Currently, 50 employees are working on site, with the workforce expected to grow to around 100 by the end of the year. The company said it is investing approximately CHF 150 mn (EUR 160 mn) in the location. Ypsomed has also secured an additional 30,000 m² of land for future expansion. The facility is certified to the international ISO 13485 standard for medical devices by TÃV Süd. Production of the first commercial batches is already underway.
Related: Long-term supply contract with Novo Nordisk
Ypsomed is also expanding its production capacity in other regions. In the US, a potential first manufacturing site is in the advanced stages of evaluation, with the project expected to launch later this year. The company has not yet disclosed specific details, however. In Schwerin, Germany, the foundation stone for a second plant was laid in spring 2025. Capacity is also being expanded at the existing sites in Burgdorf and Solothurn, Switzerland.
In the past financial year, the medical-technology company significantly increased both revenue and profit. For the current 2025/26 financial year (ending 31 March), Ypsomed is forecasting revenue growth of around 20%.
As early as November 2024, Ypsomed announced that it would strategically focus on self-injection solutions going forward. As part of this shift, the diabetes business â” including the insulin pump division â” was sold.
Plasteurope.com is a business information platform for the European plastics industry. It is part of KI Kunststoff Information and PIE Plastics Information Europe, one of the leading content providers for the European plastics industry. We offer daily updated business news and reports, in-depth market analysis, polymer prices and other services for the international plastics industry, including a suppliers guide, career opportunities, a trade name directory and videos.
